Kalbe Farma Grew By 1.41% in YTD September 2006

PT Kalbe Farma Tbk. (“Company”) today announced financial results for the quarter ended Sep 30, 2006.

Throughout the period of nine months of 2006, the Company sales performance has increased by 1.41% to Rp 4.49 trillion versus Rp 4.43 trillion last year.

Gross profit margin increased from 50.9% of Net Sales from last year to become 51% of Net Sales for the nine months period of 2006. This is due to the favorable and stable US Dollar exchange rate resulting in favorable cost of raw material that is mostly imported.

Operating expense increased by 5.27% compared to the same period last year. The Company will further make utmost efforts to minimize its expenses particularly its selling expenses so as to be in proportion with its sales growth towards the year end.

Operating Profit reached Rp 853 billion which is 4.11% lower than the previous year’s which was Rp 890 billion. Operating profit ratio decreased from 20.1% of Net Sales to become 19% of Net Sales this year.

However, the Company posted net profit of Rp 540 billion; 5.71% higher than 2005’s figure which was Rp 511 billion. The growth is mainly contributed by the increase in interest income, decrease in financial expenses and the reduction in foreign exchange loss.

CORD BLOOD STORAGE, Now Available in Indonesia

There is no need to go to Singapore to store your baby’s cord blood - which is rich in stem cells because Indonesia will have its own “Cord Blood Storage” put together by CordLife Singapore in collaboration with PT Kalbe Farma. Stem cells that may be used for therapies of cancer, heart diseases, diabetes up to bone damage is not only useful for the owner of the cord blood but also his close relatives.

The cost is considered economical. The fee for cord blood extraction is 8 Million IDR. Storage fee is 1.2 Million IDR per year. Compare the fees with storing the cord blood in Singapore which could reach up to S$ 5.000 to S$ 10.000.

The construction plan for Cord Blood Storage in Indonesia is warmly welcomed by the Health Minister, Siti Fadillah Supardi. In the press conference held by PT Kalbe Farma, in Jakarta, Saturday (14/10), the Health Minister said with the increasing number of patients suffering from degenerative diseases and blood disorders, stem cell transplantation technology is inevitable.

“The realm of health education is developing and Indonesia cannot always be left behind. All these while, mothers who had just given birth have let their babies’ cord blood be taken away. They only know about the old myths of taking the piece of umbilical cord at home,” she said.

Dr Sunny Tan Chiok Ling from CordLife Singapore explained; during pregnancy, the umbilical cord is the only life connection between the mother and the baby. If all these times, umbilical cords are discarded and buried, in 1963, the medical world found that stem cells from this cord blood and umbilical cord may be used by the bay as well as his family to cure various diseases.

“This is because the blood in the umbilical cord contains millions of stem cells which can initiate the formation of blood type similar with stem cells found in the bone marrow. The stem cells in the bone marrow and cord blood have been successfully harnessed to cure many life threatening blood disorders,” he said.

The first stem cell transplantation was done in France in 1988 for a Fanconi anemia sufferer. At present there are already more than 3.000 stem cell transplantations and more than 72 diseases cured by it. Most of them are acute illnesses such as leukemia, non-Hodgkin's Lymphoma, aplastic anemia, and autoimmune diseases.

In the future, researchers believe that stem cell may be used to repair body organs such as heart and pancreas (diabetes), and help to treat diseases namely systemic lupus erythematosus (SLE), multiple sclerosis, stroke, alzheimer, and parkinson.

The interest of Indonesia’s community to store their children’s umbilical cord in a cord blood storage seems to increase. According to Yuliana Indriati from the Kalbe Farma Stem Cells Development Division, at the moment there are about 100 people in Indonesia who stored umbilical cords in CordLife Singapore. One of them is from the baby of Maya Rumantir.

“I see the community’s enthusiasm in Indonesia to store cord blood is pretty big. Seen from the requests of some patients in a number of hospitals in Jakarta. But, because the stem cord storage facilities in Indonesia is still under development stage, the storage is done in Singapore. The cost is more expensive, which is 12 Million IDR for extraction,” said Indriati.

The request for cord blood extraction procedure is done by the patient during pregnancy. At the time of delivery, the cord blood is left in the placenta, which is clamped and cut. Using a safe technique, the doctor will put the cord blood into a blood bag.

The process is safe and painless for both the mother and the baby.

“The blood bag method is a more sterile process and storage compared to other methods. Stem cells will be stored in liquid nitrogen container at – 196 degree Celsius. It enables the cells to be preserved safely. Stem cells may be used in the future when needed,” she said.

Questioned about the storage time limit, Indri said, it is unlimited, it depends on the client’s wish. Even though the stem cell is not used on the related child, it may be used for his family. “When used on close relatives, the rejection factor is very small because it has similar genetic characteristics,” she said. (Tri Wahyuni)

Source in BAHASA: http://www.suarakarya-online.com/news.html?id=1582

Leading Indonesian pharma company, Kalbe Farma, invests in CyGenics subsidiary, CordLife Indonesia

Leading tissue and cord blood banking company CyGenics Ltd. (ASX: CYN) today announced Indonesia's leading pharma company, Kalbe Farma, has taken a 49% stake in its cord blood banking subsidiary, CordLife Indonesia.

This is a further, important step in CyGenics strategy of focusing on its core business of tissue and cord blood banking, and greatly strengthens its presence in a large and important market in the Asian region. The expansion of the Indonesian operations is in line with CyGenics' focus on revenue generating cord blood banking services and on establishing a sound presence in all major markets in the Asian region.

Kalbe Farma is the largest publicly-listed pharmaceutical company in Southeast Asia, with a market capitalisation of approximately US$1.5 billion and US$600 million in revenue in 2005. Kalbe Farma has over 12,000 employees, which includes a sales force of 6,000 covering 80% of the Indonesian consumer health market. Further, it is the dominant supplier to the Indonesian prescription pharmaceutical market.

CordLife Indonesia has been in operation since December 2003. The cord blood units have been couriered to Singapore, for processing and storage at the company's AABB-accredited facility. The volume of business in Indonesia has grown to the extent that the operations now require a processing and storage facility in the country. The investment by Kalbe Farma will enable CordLife Indonesia to proceed with these plans. The new facility is expected to be fully operational by early 2007, and the company intends to seek AABB accreditation for this facility.

Kalbe Farma will make a significant contribution towards growing the business through its vast hospital sales force of 6,000 people, and extensive hospital and birthing centre network. CordLife Indonesia will launch an expanded marketing and sales program for the cord blood banking business later this year.

"We have been looking for some time for a suitable partner towards building a business around tissue banking and cell therapy solutions in Indonesia", said Boenjamin Setiawan, President Commissioner, Kalbe Farma. "CordLife has been operating in Indonesia for some time, with a good team of people and a strong reputation. The CyGenics group has the best expertise in this region in terms of operational experience in many markets, quality standards, and so on. I believe together we will be able to do great things and lift CordLife Indonesia to the next level of growth."

"With its close proximity to Singapore and a projected five million births in 2006 alone, Indonesia has always been a key market for future expansion for our CordLife operations," said Steven Fang, Group CEO, CyGenics. "We are pleased to welcome Kalbe Farma as a valuable partner, and we look forward to being able to reaching a great many more people with our cord blood banking service."

Kalbe In-house Show & Pharma Forum 2006

Cheap Revolution influences all of daily life’s aspects. The pharmaceutical industry is no longer immune to this issue, as said by Johannes Setijono, the President Director of PT Kalbe Farma Tbk when opening Kalbe In-house Show & Pharma Forum 2006, Thursday 21 September 2006 at Cikarang, Bekasi Jawa Barat.



Cheap Revolution

According to Indonesia Innovator of the Year 2006 from CNBC Asia Pacific, Cheap Revolution is a massive event that occurred on account of globalization that overwhelms the world. Costumers are smarter in spending their money as well as increasing their demands for quality and comfort. As days passed the price for goods and services decline.

Some of the causes are: technology revolutions, real time media, the increase of productivity, price information from the internet, mass production, etc. Besides that, the pharmaceutical company in particular, is being demanded to reach a certain quality standard namely, cGMP, ISO 9001, ISO4001, OHSAS 18001 & Total Quality Management.

To achieve the above standards with high quality products and efficient cost, there is a way called Outsourcing.

Outsourcing system is commonly used by overseas companies – this benefits both parties. For the outsourcing contributor, this may decrease investments when there are new and high tech products in line. For the outsourcing recipients, the possessed capacity may be used to the maximum.

With outsourcing, the company may become tougher in facing cheap revolution. Slowly but surely, the products manufactured will become relatively cheaper, except the products that are still in patent period, said Johannes.

Can the "Local" manufactures survive without partnership?

The above question becomes the base of Santoso Oen’s explanation regarding the challenges in the world of pharmaceutical producer these days. As an example, the Director of PT Kalbe Farma Tbk quoted news regarding Vietnam’s pharmaceutical industry. Around 100 local pharmaceutical companies (out of 200) are at risk of being closed down. Some of the reasons are the increasing production costs and the demands from Vietnam’s National Agency of Drug and Food Control for higher quality. Such things may become an idea for the companies in Indonesia, both big and small to start thinking about production pattern that may depress the production and development costs, to hold back investment process cost and decrease quality management cost.


Besides taking up explanations from pharmaceutical outsourcing experts, participants can also look at the opened booths. Various booths that depicts the production process, quality control, supply chain management, packing, etc. were shown at Kalbe Farma office in Cikarang, Bekasi Jawa Barat.

Stem Cell Press Conference Symposium: New Hope in the Medical World

On 11 Augusts 2006, Medicastore participated in Stem Cell Press Conference Symposium which was held at the Anatomy Lecture Room FKUI by Fraunhofer Institute Germany working together with the University of Indonesia Medical Faculty and sponsored by PT Kalbe Farma, Tbk.

Speakers in attendance:
1. Prof. Dr. dr. M. Farid Aziz, SpOG (K), MRU FKUI Indonesia.
2. Dr. Johannes Bolze, Director and Principal Investigator Stroke Fraunhofer Institute German.
3. dr. Boenjamin Setiawan PhD, PT Kalbe Farma Tbk.
4. dr. Bambang Budi Siswanto, FIHA,. Vice Chairman of the Stem Cell Symposium Comittee

As moderators:
1. dr. Erik Tapan, MHA, Reflection of the Medical World
2. IBK Narayana Dr, Ing, Fraunhofer Representative Office Indonesia.

Hereon the detailed information:

Stem Cell = Miracle Cell
There are several diseases that are previously incurable by conventional therapies (chemotherapy and radiotherapy) such as multiple myeloma, chronic lymphatic leukemia, thalassemia major. Fortunately, now, there is a new hope.

In the last several years, there is a development in the medical world especially in the field of hematology and stem cell transplantation. “Stem Cell is the fifth phase in the medical history after the use of herbal and screening which continues to the discovery of cure for syphilis, the discovery of penicillin by Alexander Fleming and biotechnology,” said dr Boenyamin.

Stem Cell is a very unique cell because it has an amazing potential to develop and able to change into new cells or to become cells of other body organs. Stem cell has the assignment to repair abnormalities in the body and theoretically, stem cell may divide infinitely to fill other cells for the body as long as the person or animal still alive. When a Stem Cell divides or becomes other cell with more specific functions, such as muscle cell, red blood cell, brain cell, liver cell, kidney cell, etc.

The sources of Stem Cells are:
Stem cell from embryo (embryonal stem cells)Taken from an embryo in the blastoporic stage, the mass inside the cell grouped and contains embryonic stem cell. The cells are then isolated from the inside and cultured by in-vitro method. The stem cell will become specialized and then turn to be blood cells, muscle cells, liver cells and kidney cells.
Adult stem cells
One of them is hematopoietic stem cells. A stem cell that is able to create red blood cells, white blood cells and healthy blood platelets, usually found in bone marrows, periphery blood and umbilical cord blood.

“In America, a stem cell coming out from an embryo is banned by President Bush because it was considered as taking someone’s life. From 60 stem cells successfully created, in the US research unit, only 20 stem cell are still in function,” said dr. Boenyamin

Stem cells are found aplenty in the umbilical cords of newborn babies. That is why the blood from the umbilical cord can be stored and used when needed in the future. Even Korea, Thailand and Singapore have created facilities for umbilical cord blood storage. One of the banks for umbilical cord storage from newborn babies is Cordlife, Singapore. The storage costs S$2000 and there is an annual fee of S$200 for maintenance fee. “In Indonesia, the collecting of umbilical cords are available at RS Lippo Karawaci and RS Mitra Keluarga,” said Dr. Narayana.

Sources for stem cell transplant:
Family members or a donor with no family connection
Identical twins
Stem cell from the patient himself that has been stored beforehand

The Future in Indonesia
“In the medical world, especially medicine, Indonesia is above international standard,” said Dr. Narayana. Hence, initiated by PT. Kalbe Farma Tbk. Indonesia in collaboration with Fraunhofer Indonesia and several universities in Indonesia set up a group of stem cell research (ABG) with the support from the government through the Minister of Research and Technology.

Fraunhofer is a non-profit organization from Germany, which moves in the field of research and has 13.000 researchers made up of 500 professors and about 5.000-6.000 doctors. Fraunhofer’s main focus is to create a network between researchers and related institutes and henceforth found new businesses that supports research.“Fraunhofer has patented the stem cell culture and cell therapy, therefore it will act as a partner for the stem cell research in Indonesia,”verified Dr. Narayana.

ABG (Academicians, Business & Government) Is a stem cell research group made up of academicians, corporation and the government namely University of Indonesia, Bogor Institute of Agriculture, AtmajayaUniversity, PT Kalbe Farma Tbk. Lembaga Ilmu Pengetahuan Indonesia (LIPI) and Badan Penelitian dan Pengkajian Teknologi (BPPT). “The purpose of ABG is to create a focused coordination and collaboration in doing stem cell research in Indonesia, therefore it does not have to be done separately and the result could be use more effectively,” said dr.Boenyamin

The Universities are made up of educators and researchers with the hope that the research result may be enjoyed by the whole community. “The research costs may be supported by the Industry where the research may not only be used as a commodity but also reach the community,” explained Prof.Dr. Farid. Korea, UK, America and Germany pioneered the world’s stem cell research.

These three elements (academicians, business and government) will be thrown together to wipe out the stereotypes that have been formed in the community. The business stereotype is that they only look for profits, the academician stereotype is they only good for theory, but slow in practice and the government’s stereotype is that they complicate research with complex bureaucracy and very limited budget. In this case, the government is expected to be the catalyst of stem cell research in Indonesia and the Industry sector is hoped to be able to fund and even give incentive and therefore the whole Indonesian community may use the result. As comparison, other Asian countries have given high incentives for doctors who are doing stem cell research.

New Hope in the Medical World
In the human body, stem cell is usually concealed in the areas of bone marrow that are lack in oxygen. It is usually unveiled when the body suffers from an injury, and goes towards the injured areas. For example, it goes into the brain cell when the victim had a stroke, leukemia and so on. But stem cell can not help when stroke, leukemia or other diseases have become acute.

Stem cell is the new hope to cure diseases that are hard to treat. Stem cell therapy is also called cellular transplant. Stem cell may be specialized to become brain cells, heart cells, backbone marrow and other cells in the body. “First, the stem cell is cultured, for example, to be a heart cell and then the heart cell is harnessed and afterwards put into the heart through a catheter,” clarified dr.Bambang.

Stem cell has been proved to treat multiple myeloma chronic lymphatic leukemia, thalassemia major, heart miokard infarct, stroke, alzheimer, etc. Stem cell research team in Indonesia has targeted that Indonesia is able to create stem cell for stroke in the next 3-5 years. At the moment, the animal model has been developed.

Stem Cell Symposium

For more information regarding stem cell, and how to harness its potential in medical world, make sure to attend the stem cell symposium:

University of Indonesia Medical Faculty (Society Research and Dedication Manager) working together with PT. Kalbe Farma Tbk. and Journal Cermin Dunia Kedokteran (CDK) will organize a day symposium with the theme: Menyongsong Era Stem Cell di Indonesia (Greeting the Stem Cell Era in Indonesia) on Saturday, 2 September 2006 at the FKUI Hall

Registration at:

Redaksi majalah CDK (attn Dodi)

Gedung Enseval

Jl. Letjen Seprapto Kav.4

Telp:012-4208171, Fax: 012-42873685

Source in BAHASA http://www.medicastore.com

Now (2007), Indonesia has a Stem Cell and Cancer Institute
Address: Jl. Jend Ahmad Yani no. 2, Pulo Mas, Jakarta 13210 - Indonesia
Tel: +62 - 21 - 47860173

PT. Kalbe Farma Tbk. Annual General Meeting of Shareholders

In the year 2005, PT Kalbe Farma Tbk. (“the Company”) recorded net sales of Rp 5.87 trillion, which is an increase of 16.42% if compared to 2004’s figures. The growth is mainly contributed by the increase in volume sales of its health food’s products (Prenagen, Diabetasol, etc), gained market share of its energy drink (Extra Joss group), and volume sales of it’s OTC (Over The Counter) products (Promag, Mixagrip, Fatigon, Fatigon Spirit, etc).

The Company’s gross profit in 2005 was Rp 3.01 trillion. This is an increase of 22.91% if compared to the previous year’s figures. Noticeable improvement can be shown in the gross profit to net sales ratio; this has increased from 48.56% in 2004 to become 51.26% in 2005. The increase is mainly due to the continuous improvement effort by the Company to find areas of improvements in its production process so it can be more efficient. One such example is finding the right combination of product mix.

Marketing expenses in 2005 was Rp 1.55 trillion; this is 23.62% higher if compared to year 2004. Marketing expense to net sales ratio became 26.37% in 2005 from 24.84% in 2004. This is because of the increased effort in marketing effort to promote new as well as star products.

The Company recorded an increase in operating profit by 19.77% to become Rp 1.11 trillion from the previous year. This caused the operating profit to net sales ratio to increase from 18.32% to become 18.84%.

All these factors lead to an increased 2005 net profits of Rp 653 billion. This figure is 44.96% higher if compared to the figure in 2004. This growth can be achieved due to several reasons. Firstly, better performance in its overall operations. Secondly, interest rate was also higher on average in 2005 comparing to 2004. Finally, it is also due to the fact that Indonesian Rupiah strengthened considerably against United States Dollar.

The Company’s total asset value was Rp 4.73 trillion or an increase of 11.75% if compared to 2004. This is in line with the increased company size due to the merger which was effected on December 16, 2005.

1. 
   The Company’s Annual General Meeting of shareholders which was held on June 21, 2006 has resolved below matters as follows:
   1. To approve director’s annual accountability for the year ended on December 31, 2005 as well as to approve and ratify the company’s planning for year 2006;
   2. To approve and ratify the company’s yearly result for the year ended on December 31, 2005 which was audited by Public Accountant: Prasetio, Sarwoko & Sandjaja with its unqualified opinion, and to give full discharge of responsibility to the Board of Directors for their management and to the company’s Board of Commissioners for their supervision during the year ended on 31 December 2005 (acquit et de charge) as long as the results are reflected in the financial figures of Company’s yearly result for the year ended on 31 December 2005;
   3.
   a. To approve that there will be no cash dividend payout to all of Company’s shareholders;
   b. To approve that the net income in the amount of IDR 653,329,399,498 (six hundred fifty three billion three hundred twenty nine million three hundred ninety nine thousand four hundred ninety eight) is to be kept as an additional working capital for the Company;
   4.
   a. To approve the reappointment of the Board of Directors and the Board of Commissioners which will be effective starting the end of this annual general meeting of shareholders until the end of the 2008 annual general meeting of shareholders with the composition as follows:
   President Director : Johannes Setijono
   Vice President Director : Johanes Berchman Apik IbrahimVice President
   Director : Budi Dharma Wreksoatmodjo
   Director : Bernadette Ruth Irawati Setiady
   Director : Santoso Oen
   Director : Yozef Darmawan Angkasa
   Director : Vidjongtius
   Director : Herman Widjaja
   Director : Justian Sumardi
   President Commissioner : Boenjamin Setiawan
   Commissioner : Nina Gunawan
   Commissioner : Rustiyan Oen
   Independent Commissioner : Johannes Baptista Soemarlin
   Independent Commissioner : Inne Erna Adriana Soekaryo
   b. To give full authority to the meetings of the company’s Board of Commissioners to determine salary and incentive for member of Board of Commissioners and to give full authority to Board of Commissioners of the company to determine honorarium/salary for member of the company’s directors for year 2006;
   5. To give full authority to Board of Commissioners and/or Directors of the company to appoint Public Accountant listed in Capital Market Supervisory Body for auditing the company’s bookkeeping for year 2006, also to give authority to the company’s board of directors to determine their honorarium and other appointment requirements.

Source: Press Release No. 011/KFCP-DIR/PR/VI/06, dated Jun 21, 2006

BAHASA

PT Kalbe Farma Tbk was chosen as the Best Stock Issuer in Bisnis Indonesia Award Development Board

Attempts to be the best have to be done step by step. Whether the move is appropriate or not, we obviously need to do plenty of judgments and that inclues accepting judgments from outside parties. Recently, as published in Harian Bisnis Indonesia, Wednesday 21st June 2006, PT Kalbe Farma Tbk was chosen as the Best Stock Issuer in Bisnis Indonesia Award Development Board. Also, CEO of the Year 2006 went to Mr. Johannes Setijono, President Director of PT Kalbe Farma Tbk.

The Award was given on 20th June 2006 at Shangrila Hotel Jakarta
Sri Mulyani as the Minister of Finance stated in her opening speech that, ‘here, Asian companies are only a handful. Maybe only five (companies). I hope that the award may motivate more companies to compete in Asia.’

Bisnis Indonesia Award Winners 2006:

• CEO of The Year: President Director of PT Kalbe Farma Tbk, Johannes Setijono
• Best Development Board Issuer: PT Kalbe Farma Tbk
• Best Main Board Issuer: PT Berlian Laju Tanker Tbk
• Best Bank: PT Bank Rakyat Indonesia Tbk
• Best Regional Development Bank: BPD Nusa Tenggara Timur
• Best Mutual Funds: Fortis Investment
• Most Active Security Company: PT Kim Eng Securities
• Best Insurance (General) Company: PT Allianz Utama
• Best Life Insurance Company: PT Sequis Life

The awards were given to urge and motivate market participants to improve and maintain their performances, 60% is based on finance load performance, 20% on corporate governance performance and 20% on corporate action performance. Particularly on corporate governance which performance is assessed based among others on: the distribution of share ownership and the level of management adherence towards law and regulations. While corporate action is based on positive activities toward the company.

Live Interview on TVRI, Friday 23rd February 2006, at 19.30 WIB
Do not miss the interview with Mr. Johannes Setijono as CEO of the Year 2006 as well as President Director of PT Kalbe Farma Tbk, the Best Stock Issuer in Bisnis Indonesia Award Development Board live from TVRI, Friday 23rd February 2006, at 19.30 WIB.

BAHASA

“MediFlex” Turnover Reached the Top 10 New Products in Indonesia

Mediflex, the first cream in Indonesia that contains glucosamine proves to be selling well. The cream meant for knee joint disorders is in the Top 10 New Products in Indonesia, according to the May edition of Farmacia Magazine. The definition of a new product is a product that has been launched in the last 2 years. It is in accordance with PT Kalbe Farma’s commitment to always innovate, launch (and to make it a success) new products.

Dr. Martinus Zega, Mediflex’s Product Manager affirmed that one of the keys that support the recognition of this 75gr cream is because the product is the first product in Indonesia that contains glucosamine. Another thing is because the packaging is designed to be as attractive as possible; hence, patients may know the indications or benefits of the cream. The point is still not common on medications sold as ethical drugs.

Even though it falls under the category if ethical products, the cream may be bought in pharmacies and hospitals without prescriptions. Also, the product has undergone clinical tests at Cipto Mangunkusumo Hospital Jakarta and proven to be effective.

According to the plan, after a success in Indonesia, PT Kalbe Farma Tbk will sell the product overseas.

Note
MediFlex TGC may be used to cure osteoarthritis and sport injury. MediFlex TGC is the first glucosamine cream in Indonesia. With TGC (Transdermal Glucosamine Cream) technology, hence glucosamine may penetrate the skin layer to reach the painful joint. The glucosamine level in the blood for the first 2 hours is a lot higher than oral glucosamine (administered by mouth), similarly after 6 hours. A topical application cause the chance of side effects occurring to be much smaller compared to oral administration especially one regarding gastro-intestinal problems.

The Top 10 New Products in IndonesiaAccording to Forbes, IMS Health, The Top Ten New top Products (<>

1. Extra Joss, sachet 4gr
2. Lipanthyl tab, 160 mg
3. Prosogan tab, 30 mg
4. Ezetrol tab, 10 mg
5. Nexium vial dry, 40 mg
6. Dexorubic in vial dry, 50 mg
7. Mediflex cream, 75 g
8. CDR tab eff. 10
9. Hepsera tab 10 mg
10. Iressa tab 250 mg

BAHASA

Palonosetron (Paloxi) , a new anti-emetic drug from Kalbe Farma

Symposium “The 1st Tulip Oncology Summit 2006” with the topic of “From Basic to Clinic: Empowering Translational Research” was held at Sheraton Hotel Yogyakarta on April 15-16, 2006. There were around 400 participants who consist of oncologists, general physicians and medical students.
There were several interesting topics delivered, such as the new medicine Palonosetron introduced by Dr. Zakitman Jack, SpPD-HKOM and sponsored by PT. Kalbe Farma with the topic of “A Novel 5-HT3 Receptor Antagonist for Chemotherapy Induced Nausea and Vomiting”.

Hereby explained that nausea and vomiting from chemotherapy mostly is caused by the release of serotonin on the gastrointestinal mucosa, therefore the standard treatment for nausea and vomiting is based upon the serotonin antagonist. The anti-emetics from the class of serotonin antagonist which are currently available on the market do not have optimal effectivity. Therefore, PT Kalbe Farma marketed the most recent anti-emetic of serotonin antagonist class called Palonosetron. There are several advantages of Palonosetron from its pharmacological side, which has longer half life (up to 40 hours) therefore only needed once on the first day of chemotherapy with the effectivity up to days 5 and 6. Thus this can prevent the occurrence of nausea and vomiting acutely for the first 24 hours after chemotherapy up to 120 hours afterwards.
On the clinical trial phase III, Palonosetron 0.25mg compared with other serotonin antagonist such as Ondansetron and Dolasetron on the standard dose, Palonosetron has similar effectivity equal to those two drugs to prevent the side effects of nausea and vomiting within the first 24 hours. However, it is more effective after the first 24 hours of chemotherapy up to day 5 preventing the moderate and high emetogenic effect of chemotherapy.
In Indonesia, Palonosetron will launch soon with brand name: Paloxi

Media Workshop & Testimonial Book Launch PROMAG MULIA

Welfare deterioration of lower socio-economic status community and the success of pioneer PROMAG MULIA Program (2005) underlie PT Kalbe Farma Tbk to keep instituting amateur entrepreneurship trainings in 6 cities (Jakarta, Bandung, Surabaya, Makassar, Medan and Lampung). These trainings provide professional entrepreneurship knowledge of the ManagementQolbuTrainingCenter whose chair is KH Abdullah Gymnastiar from Darul Tauhid Bandung. This is the news of press release together with the Testimonial Book Launch titled “Jangan Jadi Pengusaha Bila Tidak Berani Memulai (Don’t Be An Entrepreneur If You Don’t Dare To Start)” in JakartaApril 13, 2006.
(picture: Mr Johannes Setijono with Aa Gym)

The pioneer PROMAG MULIA Program (Membangun Usaha Lewat Ilmu dan Ahklak/Establishing Business With Knowledge and Morality) attracted 20 participants from 5 cities. This exhibited the enthusiasm and expertise, furthermore motivating a book to be written, titled “Jangan Jadi Pengusaha Bila Tidak Berani Memulai” (Don’t Be An Entrepreneur If You Don’t Dare To Start). This book is a consolidation of experiences and tips to be shared by the participants for the community. This book can be obtained at the bookstores which sell Aa Gym books.

Mr. Johannes Setijono as the President Director of PT Kalbe Farma Tbk stated that: “We cannot imagine how many amateur entrepreneurs who try to build their own business independently and how big their success contributes to the Indonesian economy and welfare. Therefore, PROMAG MULIA intends to help to expand their businesses until they become durable and competitive professional entrepreneurs. With the provided assistance given, hopefully the number of entrepreneurs will be increasing year-by-year”.

This program is aimed for amateur entrepreneurs from B, C and D class with the age range of 18-30 years old, healthy, have their own business, passed the test and interview which were held in several cities.

KH Abdullah Gymnastiar (Aa Gym) as the chair of “Management QolbuTrainingCenter” stated that “Success is not something for granted but have to be earned with enthusiasm. Only entrepreneurs with good morality will be a great leader, and if there are more people with good morality then this nation will be a great nation”.

The training packages provided by PROMAG MULIA program was compiled by MQ. It is very concentrated so it requires prime health of the participants. In order to understand the allocated program, at the event of April 13, 2006, several journalists were invited to participate on the events which are held frequently by PROMAG MULIA. After this event, there were books distribution with the autograph of Mr. Johannes and Aa Gym.

PIRA Indonesian Award 2006
Recently PROMAG MULIA program won International Public Relation Association / PIRA-Indonesian Award 2006 as the best CSR Programme (Corporate Social Responsibility Programme).

- Official website, http://www.promagmulia.com/

BAHASA

DETAK, Early Cancer Detection Program approved by Indonesian Health Minister at Jakarta January 24, 2006.

According to histopathology examination in Indonesia on 1999, five leading site of cancer predominant in Indonesian population are cervical cancer, lymphoma, breast cancer, skin cancer and colon cancer. Arising from that awareness, Kalbe Farma cooperating with Dharmais Cancer Hospital launched DETAK (Deteksi Awal Kanker) or Early Cancer Detection Program.

DETAK was launched after being approved by Indonesian Health Minister, Dr. Siti Fadilah Supari, SpJP (K) at Gedung Dharma Wanita Pusat Kuningan, Jakarta on January 24, 2006. This event was followed by seminar, press conference and distribution of the book titled “Kanker, Antioksidan dan Terapi Komplementer” also some brochures.


(In the picture above from right to left: Herman Widjaja, Sutoto, Mrs. Umar Wirahadikusumah and Adji Baroto at the press conference. Click to enlarge)



Background
The background of launching this program is because cancer often being identified very late. This was attributed by fear of cancer in the common population which made people feel reluctant for examinations. Late diagnosis in the end inflicts with the rising health care cost, and decreasing the patient’s life-expectancy.
Aware with the importance of early screening, Yayasan Kanker Indonesia, Dharmais Cancer Hospital Jakarta and PT Kalbe Farma Tbk, endorsed mutual commitment to start enforcing DETAK program on November 2005.
DETAK is an educational program for the community to increase the knowledge about cancer, designed to convert the fear as to concern of cancer. This program is considered to be successful if the community already has courage to do routine medical check-up for earlier cancer screening.
DETAK program will be applied within one year by the following programs:
• Public seminars about cancer
• Press conferences
• Symposiums on cancer for journalists
• Writing contests about cancer
• Educational materials distribution such as: poster, brochure, etc
• Public and group lectures about cancer

With the strength and power of each participating side, Mr. Herman Widjaja as Kalbe Farma Director is optimist that this program will succeed. Kalbe Farma which has about 60 branches nationwide in Indonesia, is ready to support this noble program fully.
(Alongside with online electronic media such as this Kalbe Farma website)

DETAK secretariat
Jl. Swadaya Raya no. 11A, Duren Sawit Jakarta 13440
Tel.: 021-862 8557, 021-862 8584
Fax: 021-862 8584
E-mail: cakrawara@indo.net.id
Website: http://www.detak.org

BAHASA